As EGFR inhibitors had high selective cytotoxicity in A+AD cells compared with A−AD cells, we examined adding EGFR to this RET model for predicting OS in stage-1 and all stages of A+AD [2]. The gene discussed is EGFR; the disease is Alzheimer disease.